191 related articles for article (PubMed ID: 22278120)
1. IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1.
Schwab I; Biburger M; Krönke G; Schett G; Nimmerjahn F
Eur J Immunol; 2012 Apr; 42(4):826-30. PubMed ID: 22278120
[TBL] [Abstract][Full Text] [Related]
2. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin.
Leontyev D; Katsman Y; Ma XZ; Miescher S; Käsermann F; Branch DR
Transfusion; 2012 Aug; 52(8):1799-805. PubMed ID: 22257295
[TBL] [Abstract][Full Text] [Related]
3. Broad requirement for terminal sialic acid residues and FcγRIIB for the preventive and therapeutic activity of intravenous immunoglobulins in vivo.
Schwab I; Mihai S; Seeling M; Kasperkiewicz M; Ludwig RJ; Nimmerjahn F
Eur J Immunol; 2014 May; 44(5):1444-53. PubMed ID: 24505033
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of IVIG action in immune thrombocytopenic purpura.
Hansen RJ; Balthasar JP
Clin Lab; 2004; 50(3-4):133-40. PubMed ID: 15074465
[TBL] [Abstract][Full Text] [Related]
5. B cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo.
Schwab I; Seeling M; Biburger M; Aschermann S; Nitschke L; Nimmerjahn F
Eur J Immunol; 2012 Dec; 42(12):3302-9. PubMed ID: 22945870
[TBL] [Abstract][Full Text] [Related]
6. Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent in vitro and in vivo phagocytosis of blood cells.
Bazin R; Lemieux R; Tremblay T; St-Amour I
Br J Haematol; 2004 Oct; 127(1):90-6. PubMed ID: 15384982
[TBL] [Abstract][Full Text] [Related]
7. Sweetened antibodies against humoral autoimmunity: sialylated antibodies are required for IVIg-mediated therapy.
Fillatreau S
Eur J Immunol; 2014 May; 44(5):1276-80. PubMed ID: 24700289
[TBL] [Abstract][Full Text] [Related]
8. Improved mouse models for the study of treatment modalities for immune-mediated platelet destruction.
Katsman Y; Foo AH; Leontyev D; Branch DR
Transfusion; 2010 Jun; 50(6):1285-94. PubMed ID: 20088841
[TBL] [Abstract][Full Text] [Related]
9. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?
Siragam V; Brinc D; Crow AR; Song S; Freedman J; Lazarus AH
J Clin Invest; 2005 Jan; 115(1):155-60. PubMed ID: 15630455
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of action of intravenous immunoglobulins.
Baerenwaldt A; Biburger M; Nimmerjahn F
Expert Rev Clin Immunol; 2010 May; 6(3):425-34. PubMed ID: 20441428
[TBL] [Abstract][Full Text] [Related]
11. Mouse background and IVIG dosage are critical in establishing the role of inhibitory Fcγ receptor for the amelioration of experimental ITP.
Leontyev D; Katsman Y; Branch DR
Blood; 2012 May; 119(22):5261-4. PubMed ID: 22508937
[TBL] [Abstract][Full Text] [Related]
12. Specific ICAM-3 grabbing nonintegrin-related 1 (SIGNR1) expressed by marginal zone macrophages is essential for defense against pulmonary Streptococcus pneumoniae infection.
Koppel EA; Wieland CW; van den Berg VC; Litjens M; Florquin S; van Kooyk Y; van der Poll T; Geijtenbeek TB
Eur J Immunol; 2005 Oct; 35(10):2962-9. PubMed ID: 16134084
[TBL] [Abstract][Full Text] [Related]
13. Identification of a receptor required for the anti-inflammatory activity of IVIG.
Anthony RM; Wermeling F; Karlsson MC; Ravetch JV
Proc Natl Acad Sci U S A; 2008 Dec; 105(50):19571-8. PubMed ID: 19036920
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells modulate platelet activity in IVIg-mediated amelioration of ITP in mice.
Huang HS; Sun DS; Lien TS; Chang HH
Blood; 2010 Dec; 116(23):5002-9. PubMed ID: 20699442
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of intravenous immunoglobulin action in immune thrombocytopenic purpura.
Jin F; Balthasar JP
Hum Immunol; 2005 Apr; 66(4):403-10. PubMed ID: 15866704
[TBL] [Abstract][Full Text] [Related]
16. Cytokine profiles in mouse models of experimental immune thrombocytopenia reveal a lack of inflammation and differences in response to intravenous immunoglobulin depending on the mouse strain.
Leontyev D; Neschadim A; Branch DR
Transfusion; 2014 Nov; 54(11):2871-9. PubMed ID: 24826802
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia.
Crow AR; Song S; Siragam V; Lazarus AH
Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):710-3. PubMed ID: 16933274
[TBL] [Abstract][Full Text] [Related]
18. Role of intravenous immunoglobulin G in autoimmune hematologic disorders.
Blanchette VS; Kirby MA; Turner C
Semin Hematol; 1992 Jul; 29(3 Suppl 2):72-82. PubMed ID: 1509297
[TBL] [Abstract][Full Text] [Related]
19. Effects of splenectomy on immune thrombocytopenic purpura in (NZW x BXSB) F1 mice: analyses of platelet kinetics and anti-platelet antibody production.
Mizutani H; Furubayashi T; Kashiwagi H; Honda S; Take H; Kurata Y; Yonezawa T; Tarui S; Ikehara S
Thromb Haemost; 1992 May; 67(5):563-6. PubMed ID: 1519215
[TBL] [Abstract][Full Text] [Related]
20. GM-CSF and IL-4 are not involved in IVIG-mediated amelioration of ITP in mice: a role for IL-11 cannot be ruled out.
Lewis BJB; Leontyev D; Neschadim A; Blacquiere M; Branch DR
Clin Exp Immunol; 2018 Sep; 193(3):293-301. PubMed ID: 29704458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
